Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: Clinical results from a randomised phase-2 study (NordCML006)

European Journal of Haematology

Volumn 94, Issue 3, 2015, Pages 243-250

  Hjorth Hansen, Henrik ^a,b   Stenke, Leif ^c   Söderlund, Stina ^d   Dreimane, Arta ^e,f   Ehrencrona, Hans ^g   Gedde Dahl, Tobias ^h   Gjertsen, Bjørn Tore ^i,j   Höglund, Martin ^d   Koskenvesa, Perttu ^k,l   Lotfi, Kourosh ^e,f   Majeed, Waleed ^m   Markevärn, Berit ⁿ   Ohm, Lotta ^c   Olsson Strömberg, Ulla ^d   Remes, Kari ^o   Suominen, Merja ^p   Simonsson, Bengt ^d   Porkka, Kimmo ^k,l   Mustjoki, Satu ^k,l   Richter, Johan ^g  

^a TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^b NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^e LINKÖPING UNIVERSITY   (Sweden)

^f Centre of Surgery and Oncology   (Sweden)

^g LUND UNIVERSITY HOSPITAL   (Sweden)

^h OSLO UNIVERSITY HOSPITAL   (Norway)

ⁱ HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^j UNIVERSITY OF BERGEN   (Norway)

^k UNIVERSITY OF HELSINKI   (Finland)

^l HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^m STAVANGER UNIVERSITY HOSPITAL   (Norway)

ⁿ UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^o TURKU UNIVERSITY HOSPITAL   (Finland)

^p KANTA HÄME CENTRAL HOSPITAL   (Finland)

more..

Author keywords

Dasatinib; Deep response; Imatinib; Randomized controlled trial; Toxicity

Indexed keywords

DASATINIB; HYDROXYUREA; IMATINIB; NILOTINIB; ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; BCR-ABL1 FUSION PROTEIN, HUMAN; BENZAMIDE DERIVATIVE; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; THIAZOLE DERIVATIVE;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; BONE MARROW; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER PATIENT; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CHOLECYSTITIS; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOPENIA; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG FEVER; DRUG RESPONSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPEPSIA; FEMALE; FINLAND; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; HYPERTRANSAMINASEMIA; HYPOPHOSPHATEMIA; IMMUNOGLOBULIN DEFICIENCY; INTENTION TO TREAT ANALYSIS; MALE; METAPHASE CHROMOSOME; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; NORWAY; OUTCOME ASSESSMENT; PERIANAL ABSCESS; PERICARDIAL EFFUSION; PHASE 2 CLINICAL TRIAL; PHILADELPHIA CHROMOSOME POSITIVE CELL; PLEURA EFFUSION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SECOND CANCER; THROMBOCYTOPENIA; VOMITING; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG ADMINISTRATION; GENE EXPRESSION; GENETICS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; REMISSION; RISK; SURVIVAL ANALYSIS;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BENZAMIDES; DASATINIB; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; FUSION PROTEINS, BCR-ABL; GENE EXPRESSION; HUMANS; HYDROXYUREA; IMATINIB MESYLATE; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; REMISSION INDUCTION; RISK; SURVIVAL ANALYSIS; THIAZOLES;

EID: 84923445733     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/ejh.12423     Document Type: Article

References (27)

1. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003;348:994-1004.
2. Saglio G, Kim DW, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010;362:2251-9.
3. Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010;362:2260-70.
4. Larson RA, Hochhaus A, Hughes TP, et al. Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. Leukemia 2012;26:2197-203.
5. Kantarjian HM, Shah NP, Cortes JE, et al. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood 2012;119:1123-9.
6. Cortes JE, Kim DW, Kantarjian HM, et al. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial. J Clin Oncol 2012;30:3486-92.
7. Kantarjian HM, Hochhaus A, Saglio G, et al. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol 2011;12:841-51.
8. Kreutzman A, Juvonen V, Kairisto V, Ekblom M, Stenke L, Seggewiss R, Porkka K, Mustjoki S. Mono/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy. Blood 2010;116:772-82.
9. Mustjoki S, Ekblom M, Arstila TP, et al. Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy. Leukemia 2009;23:1398-405.
10. Porkka K, Khoury HJ, Paquette RL, Matloub Y, Sinha R, Cortes JE. Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion. Cancer 2010;116:377-86.
11. Mustjoki S, Richter J, Barbany G, et al. Impact of malignant stem cell burden on therapy outcome in newly diagnosed chronic myeloid leukemia patients. Leukemia 2013;27:1520-6.
12. Cross NC. Working definition and determination of Complete Molecular Response inthe CAMN107EIC01 (ENEST1st) trial; 2011 6/12/2011.
13. Cross NC, White HE, Muller MC, Saglio G, Hochhaus A. Standardized definitions of molecular response in chronic myeloid leukemia. Leukemia 2012;26:2172-5.
14. Hanfstein B, Muller MC, Hehlmann R, et al. Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). Leukemia 2012;26:2096-102.
15. Radich JP, Kopecky KJ, Appelbaum FR, et al. A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia. Blood 2012;120:3898-905.
16. Jabbour E, Kantarjian HM, Saglio G, et al. Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). Blood 2014;123:494-500.
17. Hehlmann R, Lauseker M, Jung-Munkwitz S, et al. Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-alpha in newly diagnosed chronic myeloid leukemia. J Clin Oncol 2011;29:1634-42.
18. Hochhaus A, O'Brien SG, Guilhot F, et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 2009;23:1054-61.
19. Preudhomme C, Guilhot J, Nicolini FE, et al. Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia. N Engl J Med 2010;363:2511-21.
20. Baccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 2013;122:872-84.
21. Hoglund M, Sandin F, Hellstrom K, et al. Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry. Blood 2013;122:1284-92.
22. Santos FP, Kantarjian H, Fava C, O'Brien S, Garcia-Manero G, Ravandi F, Wierda W, Thomas D, Shan J, Cortes J. Clinical impact of dose reductions and interruptions of second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukaemia. Br J Haematol 2010;150:303-12.
23. La RP, Martiat P, Leitner A, Klag T, Muller MC, Erben P, Schenk T, Saussele S, Hochhaus A. Improved tolerability by a modified intermittent treatment schedule of dasatinib for patients with chronic myeloid leukemia resistant or intolerant to imatinib. Ann Hematol 2013;92:1345-50.
24. Visani G, Breccia M, Gozzini A, et al. Dasatinib, even at low doses, is an effective second-line therapy for chronic myeloid leukemia patients resistant or intolerant to imatinib. Results from a real life-based Italian multicenter retrospective study on 114 patients. Am J Hematol 2010;85:960-3.
25. Ross DM, Branford S, Seymour JF, et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood 2013;122:515-22.
26. Mahon FX, Rea D, Guilhot J, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 2010;11:1029-35.
27. Hehlmann R, Muller MC, Lauseker M, et al. Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-Study IV. J Clin Oncol 2014;32:415-23.